HIGHLIGHTS
SUMMARY
(Riu-Viladoms et_al, 2019; Wang et_al, 2020a; Wang et_al, 2020b). Oncology pharmacists have demonstrated their contributions in optimizing treatment outcomes and enhancing patient satisfaction in follow-up programs for oral antitumor drugs (Bertsch et_al, 2016; Ribed et_al, 2016; Riu-Viladoms et_al, 2019; Collado-Borrell et_al, 2020; Khrystolubova et_al, 2020). To address this challenge, an oncology pharmacist-driven follow-up program was established to provide pharmaceutical care for ambulatory ovarian cancer patients (including epithelial ovarian, fallopian tube or primary peritoneal cancer patients) receiving olaparib in a tertiary cancer-specialized hospital in China. The authors have . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.